News

CFRA Downgrades Caesars Entertainment While Adjusting Price Target

CFRA Downgrades Caesars Entertainment While Adjusting Price Target

CFRA Downgrades Caesars Entertainment to Sell

Caesars Entertainment (NASDAQ:CZR) has recently faced a shift in its market evaluation as CFRA Services downgraded the company's shares from Hold to Sell. This downgrade aligns with a new stock price target set at $35, a decrease from the previous target of $39. The reduction in the price target is grounded in an estimated valuation of the company’s 2025 earnings before interest, taxes, depreciation, and amortization (EBITDA), applying a multiple of 8.5 times. This estimate is slightly lower than the company’s average forward EV/EBITDA multiple of 8.6x over the past year.

Reasons for the Downgrade

CFRA’s analysts indicate that Caesars Entertainment is expected to continue trading within a limited range in terms of its forward EV/EBITDA metrics. This perspective has resulted in a downward revision of the firm’s 2024 earnings per share (EPS) forecast, which now stands at a negativity of $0.05 versus the previous estimate. Meanwhile, the 2025 EPS estimate is maintained at $0.75. The company reported a normalized Q3 EPS of negative $0.04, which failed to meet expectations by $0.25, alongside Q3 revenues totaling $2.87 billion, slightly behind market estimates.

Performance Overview in Q3

The segment performance of Caesars Entertainment during the third quarter reflected significant variations. Las Vegas revenues indicated a modest year-over-year decline of 1.3%, whereas regional revenues saw a sharper drop of 7.6%. In contrast, the Caesars Digital division witnessed growth of an impressive 40.9%. The adjusted EBITDA for the Las Vegas segment declined by 2.1%, and the regional segment experienced a 13.4% fall, while the Digital segment notably surged to $52 million, up considerably from $2 million in the same period last year.

Strategic Moves for Financial Stability

Amid these financial struggles, analysts from CFRA suggest that Caesars will likely continue divesting minor assets to raise cash. The firm's struggles to achieve sufficient earnings before interest and taxes (EBIT) necessary for covering its interest expenses have led to cautious observations regarding the company’s future performance. Furthermore, the analysts propose that there are potentially more attractive investment avenues presently available in the Casino and Gaming sector.

Recent Strategic Developments

In a strategic maneuver to bolster its financial standing, Caesars Entertainment has announced plans to sell the LINQ Promenade for $275 million. This transaction, involving a joint venture formed by TPG Real Estate and Acadia Realty, is anticipated to conclude by the fourth quarter of 2024. This strategic decision forms part of Caesars' broader initiative to streamline its asset portfolio and achieve its debt reduction objectives.

Financial Results and Market Challenges

The Q3 earnings report revealed an unexpected loss of four cents per share, starkly contrasting the anticipated profit of 12 cents per share. The revenue reported for the quarter ending September 30 also saw a decline of 4%, reaching $2.87 billion, lower than the expected $2.92 billion. Factors cited for this shortfall included heightened competition and disruptions resulting from construction in regional markets. Notably, the regional segment sales declined to $1.45 billion.

Looking Ahead with Cautious Optimism

Despite faced challenges, the Caesars Digital segment established a new quarterly record for Adjusted EBITDA with $52 million, driven by substantial growth in net revenues of over 40%. In light of ongoing financial operations, the company has successfully closed a $1.1 billion senior unsecured refinancing deal. This new financing could potentially translate into interest expense savings for the company in 2025, providing a more robust financial foundation as it navigates through an evolving economic landscape.

Frequently Asked Questions

What was the reason for CFRA's downgrade of Caesars Entertainment?

CFRA downgraded Caesars due to concerns about the company's narrow forward EV/EBITDA multiple range and increased competition impacting its performance.

What is the new price target set by CFRA for Caesars Entertainment?

The new price target set by CFRA for Caesars Entertainment is $35, down from the previous target of $39.

How did Caesars Entertainment perform in the third quarter of the fiscal year?

Caesars reported a Q3 loss of $0.04 per share, with revenues of $2.87 billion, which was below market expectations.

What strategic moves is Caesars making to improve its finances?

Caesars is divesting smaller assets and has planned to sell the LINQ Promenade to reduce debt and streamline its assets.

What has been the performance of the Caesars Digital segment?

The Caesars Digital segment experienced a remarkable 40.9% growth, achieving a quarterly record for Adjusted EBITDA at $52 million.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

U Power Limited Advances Electric Vehicle Solutions in Europe

Updated Category News Views 239

U Power Limited Expands Its European Reach U Power Limited (Nasdaq: UCAR) is making significant strides in the electric vehicle (EV) landscape. The company, known for its innovative battery-swapping technology, has announced an exciting joint venture that enhances their presence in the European market. This strategic move is expected to reshape how electric mobility is...

Continue Reading
UKG Stands Out as a Top Leader in Workforce Management Solutions

Updated Category News Views 163

UKG Secures Top Spot in Workforce Management UKG, a leading provider in HR, payroll, workforce management, and cultural solutions, has recently earned recognition for its exceptional contributions to the workforce management field. The company has been named a Leader in the NelsonHall New World Workforce Management 2024 evaluation, showcasing its strong performance across...

Continue Reading
Prominent Movers in Today's Market: Micron, Accenture Rise

Updated Category News Views 141

As the trading day unfolds, the US stock market is witnessing a shift, with several companies experiencing significant movements in their stock prices. Recent trends show that investors are closely monitoring the market after a minor disruption in gains. Micron's Robust Performance Micron Technology (NASDAQ: MU) has captured the spotlight today, with shares surging by an...

Continue Reading
Celebrate 1.5 Years of Obey Me! Nightbringer with Exciting Events

Updated Category News Views 85

Celebrating 1.5 Years of Obey Me! Nightbringer Obey Me! Nightbringer is reaching a significant milestone, celebrating its 1.5-year anniversary. This beloved mobile game from NTT Solmare has captured the hearts of players around the globe, and to acknowledge this momentous occasion, the developers are rolling out a variety of exciting events. Four Exciting Events for...

Continue Reading
Celebrating Innovation: 2026 sofi™ Awards Winners Unveiled

Updated Category News Views 219

Celebrating Culinary Excellence: The 2026 sofi™ Awards NEW YORK — The Specialty Food Association (SFA) revealed the much-anticipated results of the 2026 sofi™ Awards at the Winter FancyFaire event. This celebrated gathering brought together industry leaders, chefs, makers, and buyers to applaud the finest in specialty food and beverage innovation. A Night of...

Continue Reading